Literature DB >> 10764926

The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine.

K Ito1, T Ohmori, T Abekawa, T Koyama.   

Abstract

The GABA-benzodiazepine neurotransmission has been reported to be implicated in various forms of plasticity such as kindling and learning. In a previous study, we have shown that clonazepam (CZP), a GABA-benzodiazepine agonist, prevents the acquisition of behavioral sensitization to methamphetamine (MA). The present study was conducted to extend this finding by examining the effect of flumazenil (Flu), a GABA-benzodiazepine antagonist on the prevention by CZP. Rats (male Wistar-King rats) treated with MA (1 mg/kg, SC) for 10 days showed significantly enhanced motor activity compared to those treated with saline when tested with MA (1 mg/kg) after a 7-8-day withdrawal, indicating the acquisition of behavioral sensitization. Representing the previous finding, pretreatment with CZP (0.5 mg/kg) prior to MA administration prevented the acquisition of the phenomenon. Pretreatment with Flu (10 mg/kg) prior to MA administration has no influence on the acquisition of sensitization. However, pretreatment with Flu prior to CZP administration reversed the inhibitory effect of CZP. CZP showed no effect on the expression of sensitization in the sensitized rats when given prior to the MA readministration. These results strengthen the suggestion that stimulation of GABA-benzodiazepine receptors plays a role in the acquisition but not in the expression of behavioral sensitization to MA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764926     DOI: 10.1016/s0091-3057(99)00263-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine.

Authors:  K Ito; T Abekawa; T Koyama
Journal:  Psychopharmacology (Berl)       Date:  2006-04-01       Impact factor: 4.530

2.  Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.

Authors:  Walter Ling; Steven Shoptaw; Maureen Hillhouse; Michelle A Bholat; Charles Charuvastra; Keith Heinzerling; David Chim; Jeffrey Annon; Patrick T Dowling; Geetha Doraimani
Journal:  Addiction       Date:  2011-11-15       Impact factor: 6.526

3.  Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions.

Authors:  Junichi Kitanaka; Nobue Kitanaka; Motohiko Takemura
Journal:  Drug Target Insights       Date:  2006-11-09

Review 4.  The role of the GABA system in amphetamine-type stimulant use disorders.

Authors:  Dongliang Jiao; Yao Liu; Xiaohong Li; Jinggen Liu; Min Zhao
Journal:  Front Cell Neurosci       Date:  2015-05-05       Impact factor: 5.505

5.  Argon prevents the development of locomotor sensitization to amphetamine and amphetamine-induced changes in mu opioid receptor in the nucleus accumbens.

Authors:  Hélène N David; Martine Dhilly; Géraldine Poisnel; Mickael Degoulet; Cédric Meckler; Nicolas Vallée; Jean-Éric Blatteau; Jean-Jacques Risso; Marc Lemaire; Danièle Debruyne; Jacques H Abraini
Journal:  Med Gas Res       Date:  2014-12-29

6.  Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens.

Authors:  H N David; M Dhilly; M Degoulet; G Poisnel; C Meckler; N Vallée; J-É Blatteau; J-J Risso; M Lemaire; D Debruyne; J H Abraini
Journal:  Transl Psychiatry       Date:  2015-07-07       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.